Aims Treatment with the glycoprotein IIb/IIIa receptor antagonist abciximab before and during coronary intervention in refractory unstable angina improves early outcome. We collected 4-year follow-up data to assess whether this benefit is sustained. Additionally, we investigated the predictive value of baseline troponin T and CRP for long-term cardiovascular events.
Introduction
Acute coronary syndromes have been associated with inflammation and thrombosis. Markers for inflammation, such as C-reactive protein (CRP) 1, 2 or interleukin-6 3 are associated with impaired outcome in patients with coronary heart disease. Cardiac troponin T (TnT) and troponin I are very sensitive and specific markers of myocardial necrosis in patients with acute coronary syndromes and identify patients at high risk for subsequent events. [4] [5] [6] Small amounts of necrosis detected by elevated troponin levels are probably caused by micro-emboli from thrombus at the site of unstable plaques. Accordingly elevated cardiac troponin levels may be considered markers of active thrombosis.
In the CAPTURE trial 7 of patients with refractory unstable angina, undergoing percutaneous coronary intervention (PCI), elevated CRP and TnT were both associated with impaired outcome at 6 months. Treatment with the glycoprotein IIb/IIIa receptor antagonist abciximab in CAPTURE did reduce the risk of early thrombotic complications (death or MI) particularly in patients with elevated troponin. 8 Also in several other studies treatment with abciximab and other glycoprotein IIb/IIIa receptor antagonists resulted in improved outcome in patients with acute coronary syndromes without persistent ST-segment elevation. 9, 10 However, to date only one trial has reported long-term results of treatment with a glycoprotein IIb/IIIa receptor antagonist, 11 while another study reported longterm predictive value of baseline troponin T and CRP for cardiovascular events. 12 In the latter study, however, no relationship of these markers to the treatment was reported. We collected follow-up data of patients enrolled in the CAPTURE study with a median follow-up of 4 years, and studied the effect of treatment with abciximab and the association with high troponin T and CRP levels.
Methods

Patients and treatment
The CAPTURE protocol has been described in detail. 7 Briefly, patients were eligible if they had refractory unstable angina, defined as chest pain at rest with concomitant ECG abnormalities compatible with myocardial ischemia (ST-depression, ST-elevation or T-wave inversion), and one or more episodes of typical chest pain or ECG abnormalities during at least 2 h treatment with i.v. heparin and nitrates. The most recent ischemic episode should have occurred within 48 h before enrolment, corresponding to Braunwald class III unstable angina. All patients had undergone coronary angiography, and percutaneous coronary intervention (PCI) was scheduled within 18-24 h after the start of the study medication. After informed consent, patients were randomly assigned to abciximab (ReoPro, Centocor B.V., Leiden, The Netherlands; 0.25 mg . kg −1 bolus plus 10 µg . min −1 continuous infusion) or placebo. Study medication was started within 2 h of randomization and continued until 1 h after the procedure. All patients received aspirin, heparin and nitrates, whereas -blockers, calcium channel antagonists, and other cardiovascular drugs were given at the discretion of the investigator.
Serum samples drawn at the time of randomization were available for determination of troponin T and CRP. Troponin T was measured using a one-step enzyme immunoassay based on electrochemiluminescence technology (Elecsys 2010, Boehringer Mannheim, Germany). The lower detection limit of this assay was 0.01 mg . l 
End-points
The primary end-point of CAPTURE was a composite of 30-day all-cause mortality, myocardial infarction (MI) or an urgent intervention for treatment of recurrent ischaemia. Follow-up at 6 months was part of the study protocol. MI during the index hospitalization was defined by CK-MB or CK levels exceeding three times the upper limit of normal in two samples and increased by 50% over the previous value, or an ECG with new significant Q waves in two or more contiguous leads. Myocardial infarction after discharge was defined by CK-MB or CK levels exceeding twice the upper limit of normal, or new significant Q waves in two or more contiguous ECG leads. A clinical end-point committee adjudicated these events. Survival status and information on myocardial infarction and coronary revascularization procedures were collected for all 1234 patients who were alive 6 months after randomization. Follow-up was obtained from the treating physician, the patient or municipal registries and was not adjudicated.
Data analysis
Data were analysed according to the intention to treat principle. Continuous variables were summarized by median values with corresponding 25th and 75th percentiles. Discrete variables were summarized in terms of frequencies and percentages. Differences between abciximab and placebo were evaluated by Fisher's exact or Wilcoxon tests. Kaplan-Meier analyses were performed to evaluate the occurrence of events over time (obviously the 6% of patients without information beyond the 6 month period contribute to the time-to-event analysis only up to 6 months). Log-rank tests were applied to evaluate differences between abciximab and placebo. Multivariable Cox proportional hazards regression analyses were applied to evaluate the relation between troponin T, CRP and long-term outcome, adjusted for known clinical determinants of adverse outcome in acute coronary syndromes. P values were two-sided, with P≤0.05 being considered significant.
Results
Baseline characteristics and clinical outcome
A total of 1265 patients were enrolled in the CAPTURE trial. Mortality during the first 6 months of follow-up was 2.5%. Of the remaining 1234 patients, follow-up information was obtained in 1157 patients (94%) ( Table 1) . Sixty-four patients did not respond on (repeated) requests for information; one patient withdrew his informed consent, while no information of their current address was available in 12 patients. The numbers of patients without follow-up were equally distributed over the two treatment arms (6.0% in both the placebo group and the abciximab group). Median follow-up since randomization was 48 months (inter-quartile range: 38 to 55 months). Patients with extended follow-up, were 4 years older (62 vs 58 years; P<0.05, Table 1 ), but there were no other major differences between patients with and without extended follow-up. The rate of death or myocardial infarction was consistently lower over 4 years in patients randomized to abciximab (Table 2) , although statistical significance was not maintained (Fig. 1) . Four-year mortality rates were Data presented are median (25th, 75th percentiles) or percentages. CABG = coronary bypass surgery; CHF = congestive heart failure; MI = myocardial infarction; PCI = percutaneous coronary intervention; PVD = peripheral vascular disease.
* P<0.05.
similar: 6.4% in patients randomized to abciximab and 6.0% for placebo.
Troponin T
The initial large and significant difference in death or MI favouring abciximab among patients with troponin T > 0.1 µg . l −1 at randomisation was maintained throughout follow-up. At 4 years, death or myocardial infarction in patients with a positive troponin T occurred in 16.9% for those receiving abciximab and in 28.4% for those receiving placebo (P = 0.015). Four-year mortality rates were 8.7% and 11.7% (P = ns) in troponin T-positive patients randomized to abciximab and placebo, respectively (Table 3) . Initially abciximab reduced event rates after randomization as compared to placebo in both troponin-positive and troponin-negative patients, while the absolute event reduction was most pronounced in the troponin-positive cohort. However, during follow-up the initial (modest) benefit of abciximab was further reduced in the troponin negative patients. In fact, the long-term incidence of death or MI among troponin-positive patients randomized to abciximab was similar to the troponin-negative patients, regardless of the treatment allocation in this latter group (Fig. 2) . With regard to the composite end-point (death, myo cardial infarction or any revascularization-PTCA, CABG) some evidence of a differential treatment effect between troponin T-positive and negative patients was found (P = 0.065). In the troponin T-positive patients an event occurred in 42.7% with abciximab and in 50.5% with placebo (P = 0.094). In the troponin T-negative patients these event rates were 48.7% and 43.6% (P = 0.44), respectively.
C-reactive protein
CRP upon admission was also a determinant of long-term outcome, as patients with a high CRP (>10 mg . l −1 ) had a significantly higher incidence of death or MI than those with normal CRP (23.0% vs 15.3%; P = 0.011) (Fig. 3 ). Mortality at 4 years was 9.2% for patients with high CRP and 3.9% for patients with low CRP (P = 0.001). However, in contrast to troponin, the risk reduction by abciximab was not related to CRP status (differential treatment effect: P = 0.56). Death or a myocardial infarction at 4 years occurred in 18.9% of the patients with high CRP receiving abciximab and in 23.0% (P = 0.29) for patients having a high CRP receiving placebo. For a low CRP it was 11.4% and 15.3% (P = 0.16) respectively (Table 4 ). In the CRP-positive patients at 4 year death, myocardial infarction or revascularization occurred in 57.6% with abciximab and in 50.0% with placebo (P = 0.56). In the CRP-negative patients this was 47.0% and 42.7% (P = 0.79) respectively.
Troponin T and C-reactive protein
Troponin T and CRP had independent prognostic value (Fig. 4) . Patients with both elevated troponin T and CRP had the highest 4-year event rate (death or MI: 16.8%), whereas patients with a low CRP and negative troponin had the lowest event rate (3.9%; P<0.001). Both troponin T (hazard ratio 1.7 (1.1-2.5), P = 0.009) and elevated CRP (hazard ratio 1.6 (1.1-2.4), P = 0.013) remained independently significant determinants of long-term cardiac outcome after correction by multivariable analysis for other established risk factors: age, sex, diabetes, hypertension, smoking, hypercholesterolemia, previous cardiovascular disease i.e. myocardial infarction, heart failure, PTCA, CABG or stroke-and peripheral vascular disease. The long-term risk reduction with abciximab was most pronounced in troponin T-positive patients regardless of CRP value (hazard ratio 0.44 vs 0.92, abciximab vs placebo respectively; P = 0.073).
Discussion
Abciximab was the first glycoprotein IIb/IIIa receptor blocker to demonstrate improved outcome at 30-days in patients with acute coronary syndromes scheduled to undergo percutaneous coronary intervention (PCI). These findings from CAPTURE 7 are consistent with those from all other trials with abciximab in patients undergoing PCI, for stable or unstable angina or myocardial infarction, with balloon angioplasty, stent or other devices. 11, [13] [14] [15] [16] A combined analysis of all studies revealed a significant reduction of mortality at follow-up in patients receiving abciximab at the time of PCI, in addition to the reduction in death and myocardial infarction and urgent reintervention. 17 Patients in CAPTURE with a high troponin T value at enrolment, and patients having an elevated CRP were at increased risk for death or myocardial infarction during follow-up. A positive CRP became predictive as of 6 months follow-up. These results confirm those of the FRISC II study, 12 in which the prognostic value of troponin T and CRP was studied in unstable angina patients treated with dalteparin. In both studies elevated levels of troponin T and CRP were strongly and independently related to the long-term risk of death from cardiac causes. A unique finding in CAPTURE is the marked acute and long-term treatment benefit with abciximab in patients with elevated troponin T irrespective of the CRP level (Fig. 4) .
The present findings support the concept that the pathophysiology of atherosclerosis in acute coronary syndromes is multifactorial, with a chronic (inflammatory) basis 18 and an acute thrombotic exacerbation. [19] [20] [21] Inflammation may result in plaque instability, fissuring or rupture, with resulting local thrombosis and micro-embolization. This results in distal thrombotic occlusion and myocardial necrosis as detected by elevated cardiac troponin T. These local thrombotic events are in fact ameliorated by PCI, as is evident from the myocardial infarction event curves in CAPTURE and in other studies. Abciximab and other glycoprotein IIb/IIIa receptor antagonists inhibit platelet aggregation and thus reduce thrombotic complications associated with percutaneous coronary intervention, when started early before PCI, 22 particularly in patients with elevated cardiac troponin T. In contrast, elevated CRP is a marker of a chronic inflammatory process in the coronary wall 23 resulting in repetitive occurrences of cardiovascular events. 2, 24, 25 In patients undergoing coronary angioplasty cardiac events at 1 year and beyond are predicted by high preprocedural levels of CRP. 26 Short-term therapy with abciximab provides no protection against these events. Although abciximab has demonstrated antiinflammatory effects, which may ameliorate the acute inflammatory process 27 and lower CRP caused by PCI 28 it apparently does not control the underlying inflammatory process as a cause of elevated CRP that is associated with long-term risk. Also, prolonged treatment with an oral glycoprotein IIb/IIIa receptor antagonist provides no benefit. 29 In fact mortality was increased in five studies with these latter agents, possibly as a result of a proaggregating effect of glycoprotein IIb/IIIa receptor antagonists at the low doses which were given. 29 
Limitations to this study
The follow-up data was obtained either from the physicians, the municipal registries or directly from the patient. The clinical event committee did not adjudicate the follow-up data, accordingly criteria for myocardial infarction might differ between investigators and some events may have been missed. Seventy-seven patients were lost to followup. They were significantly younger, which could explain their mobility and tendency not to reply. Yet missing data were evenly distributed and thus are unlikely to be biased. Patients with possible chronic infections of different origin resulting in elevated CRP at baseline were not specifically recorded and could not be removed from this analysis. However, as in most clinical trials patients with 'significant non-cardiac disease' were excluded.
In the analyses, arbitrarily cut-off values for troponin T (>0.1 µg . l −1 ) and CRP (>10 mg . l −1 ) were applied. A more detailed subgroup analysis of troponin T and CRP revealed similar results (Fig. 5) .
Conclusion
This study confirms the value of abciximab in patients undergoing percutaneous intervention for refractory unstable angina pectoris and support the recommendations in the European and other guidelines for routine troponin T testing in patients presenting with chest pain in an emergency department. [30] [31] [32] Both troponin T and CRP are independent predictors of impaired long-term outcome. Troponin T is a powerful indicator for a treatment benefit with abciximab in patients with refractory angina undergoing PCI. If troponin T is positive and there are no contra-indications, abciximab or another glycoprotein IIb/IIIa receptor blocker should be given, and a percutaneous intervention should follow with at least 1 h, but preferably 12 h of infusion. 17, 22, 33 Future studies with antiinflammatory therapy that is more potent than aspirin should assess a potential additional long-term benefit in patients with unstable angina. The baseline CRP level may serve as an indicator for use of such antiinflammatory therapy.
